N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(6-quinolyl)ethynyl]-benzohydrazide | 1388804-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(6-quinolyl)ethynyl]-benzohydrazide
• 英文别名: 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-6-ylethynyl)benzoyl]benzohydrazide
• CAS: 1388804-02-1
• 化学式: C₂₇H₂₀ClN₃O₂
• 分子量: 453.928
• InChiKey: NHVBKVNUKHEGQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS
  申请人：Sun Pharma Advanced Research Company Limited

  公开号：EP2665709B1

  公开（公告）日：2016-12-07
• [EN] N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL) ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] N'-(2-CHLORO-6-MÉTHYLBENZOYL)-4-MÉTHYL-3-[2-(3-QUINOLYL) ÉTHYNYL]-BENZOHYDRAZIDE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2022024072A1

  公开（公告）日：2022-02-03

  The present invention provides a method for preventing or treating Alzheimer's disease and symptoms thereof comprising administering to a subject in need thereof a therapeutically effective amount of N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or a its pharmaceutically acceptable salts, wherein the prevention and/or treatment of said disease and symptoms thereof is achieved by inhibition of amyloid-beta (Aβ) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof. Also disclosed is the use of a therapeutically effective amount of N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or its pharmaceutically acceptable salts to inhibit amyloid-beta (Aβ) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof.